Merus to Present at the H.C. Wainwright Global Investment Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference.

The webcast of the presentation will be available on-demand starting on May 24, 2022 at 7:00 a.m. ET and will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.

About MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
[email protected]

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
[email protected]

You May Also Be Interested In

• XRP News Today: Ledger Fix Faces November Delay as XRP Nears $1.32 and Remittix’s Raise Hits $33M
• Vmake Labs Launches All-in-One Halloween Social Video Toolkit for SMBs
• Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma